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Abstract
Background: A recent meta-analysis of drug effects in patients with hypertension claims that all
β-adrenergic blockers are equally effective but less so than other antihypertensive drugs. Published
comparisons of the β-adrenergic blocker atenolol and non-atenolol β-adrenergic blockers indicate
different effects on death rates, arrhythmias, peripheral vascular resistance and prognosis post
myocardial infarction, all in disfavour of atenolol. In keeping with these findings, the data presented
in the meta-analysis indicate that atenolol is less effective than the non-atenolol β-adrenergic
blockers both when compared with placebo and with other antihypertensive drugs. These findings
were not, however, statistically significant.
Methods: We performed an additional analysis with a Bayesian statistical method in order to make
further use of the published data.
Results: Our calculations on the clinical data in the meta-analysis showed 13% lower risk (risk
ratio 0.87) of myocardial infarction among hypertensive patients taking non-atenolol β-adrenergic
blockers than among hypertensive patients taking atenolol. The 90 % credibility interval ranged
from 0.75 to 0.99, thereby indicating statistical significance. The probability of at least 10% lower
risk (risk ratio ≤ 0.90), which could be considered to be of clinical interest, was 0.69.
Conclusion: Taken together with the other observations of differences in effects, we conclude
that the claim that all β-adrenergic blockers are inferior drugs for hypertensive patients should be
rejected. Atenolol is not representative of the β-adrenergic blocker class of drugs as a whole and
is thus not a suitable drug for comparisons with other antihypertensive drugs in terms of effect.
The non-atenolol β-adrenergic blockers should thus continue to be fundamental in
antihypertensive drug treatments.
Background
In a recent meta-analysis, Lindholm, Carlberg and Samu-
elsson claim that, in patients with hypertension, the β-
adrenergic blocker atenolol is no different from other β-
adrenergic blockers in terms of effects on hard endpoints
[1]. This assertion brings to mind the HAPPHY trial [2] in
which patients on atenolol showed higher death rates and
patients on metoprolol lower death rates than did
patients taking diuretics. The difference between the two
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outcomes was not statistically significant. For other end-
points, only pooled results were released from that study.
Animal studies
Atenolol is water-soluble and is therefore distributed to
the brain to a much lower extent than most other β-adren-
ergic blockers, which are lipid-soluble. It has been
hypothesized that central nervous stimulation of the vagal
tone by β-adrenergic blockers counteracts a liability
towards ventricular fibrillation. In this connection, water-
soluble atenolol is far less effective than a lipid-soluble β-
adrenergic blocker such as metoprolol. Unfortunately,
this contention has been studied only in dogs and pub-
lished only in abstract form [3].
Pathophysiology
Somewhat surprisingly, long-term (> 6 months) exposure
of hypertensive patients to β-adrenergic blockers results in
peripheral vasodilatation. This occurs with metoprolol
and other β-adrenergic blockers, as well as with other
drugs, but not with atenolol [4]. A corresponding differ-
ence was found between atenolol and the various other
drugs as regards the media to lumen ratios of small arter-
ies.
Post myocardial infarction
Unlike the other β-blockers, atenolol has not been shown
to improve the long-term prognosis after myocardial inf-
arction [5], nor has it been tested and shown to be an
effective treatment for heart failure.
In light of the above we examined the summaries of the
data in the published meta-analysis [1]. The authors
found that the risk ratio for occurrence of myocardial inf-
arction in hypertensive patients was (with 95 % confi-
dence intervals) 0.86 (0.67 – 1.11) for non-atenolol β-
blockers compared with other antihypertensive drugs but
for atenolol versus other antihypertensive drugs the risk
ratio was 1.05 (0.91 – 1.21). This strongly indicates a dif-
ference between non-atenolol β-blockers and atenolol.
Moreover, a similar difference was found when non-aten-
olol β-blockers and atenolol were compared with placebo,
with a risk ratio of 0.89 (0.74 – 1.06), i.e. decreased risk
for the former but a risk ratio of 0.99 (0.83 – 1.19), i.e. no
decreased risk for atenolol.
We undertook the task of finding numerical expressions
for the suspicion of a difference between atenolol and
non-atenolol β-blockers by using the data available in the
meta-analysis [1].
Methods
We combined the information provided by the two sets of
data, thereby obtaining stronger statistical power. Eight of
the studies in the analysis compared atenolol and non-
atenolol β-blockers, respectively, with other antihyperten-
sive drugs and six compared atenolol and non-atenolol β-
blockers, respectively, with placebo. We used a previously
described Bayesian procedure [6] and first combined the
results of studies in similar treatment groups, assuming
that the relative effects of the treatment in the various
studies were comparable, even though the absolute risks
might differ. This is a natural assumption to make in this
context as the basis of the Bayesian analysis in which
results from different studies are combined. Generally, it
is difficult to verify the validity of this assumption against
data. However, from the data in the published meta-anal-
ysis [1] the assumption seems reasonable, except for the
MRC Old comparison of atenolol with other antihyper-
tensive drugs. Hence, calculations were also carried
through without this comparison.
We then calculated the relative risk of non-atenolol β-
blockers against atenolol by dividing the corresponding
risk ratios. Finally, based on the 8 and 6 studies respec-
tively, we combined the two estimates of the risk ratios for
myocardial infarction in patients treated with non-aten-
olol β-blockers versus atenolol by simply updating one
with the other by means of Bayes' formula.
Results
Table 1 shows our findings, indicating that the frequency
of myocardial infarctions is 13 % lower in patients on a
non-atenolol β-blocker compared with patients on aten-
olol based on all 14 studies. This outcome was to be
expected, since it agrees with previously published obser-
vations [2], which provide justification for relying on the
90 % credibility interval. This interval 0.750 – 0.992 has
an upper border slightly less than unity. The 95 % credi-
bility interval was 0.727 – 1.023. The probability of at
least 10% lower risk (risk ratio ≤ 0.90), which could be
considered to be of clinical interest, was 0.689. The results
are slightly weaker when the MRC Old study is excluded
(Table 1).
Discussion
The present additional statistical analysis of the published
data [1] thus shows a different outcome for atenolol in
relation to the non-atenolol β-blockers, in disfavour of
atenolol based on all 14 studies. Our finding also agrees
with statements by Carlberg, Samuelsson and Lindholm
in their earlier meta-analysis [7]. One of the implications
of this different outcome is that atenolol is not represent-
ative for the β-adrenergic blocker class of drugs as a whole.
Observations relating to atenolol do not necessarily apply
to other β-adrenergic blockers. A similar reservation has
also been made recently by others [8]. Therefore we do
not agree with an editorial on the publication of the
ASCOT trial and the meta-analysis, which advocates that
the current guidelines for the treatment of hypertensionPublish with BioMed Central    and   every 
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should be changed in disfavour of all β-adrenergic block-
ers [9].
Conclusion
Claims have been made that β-adrenergic blockers are
inferior drugs when used to treat patients with hyperten-
sion. We suggest that a recent meta-analysis shows that
these claims are correct only in the case of atenolol. We
have substantiated this suggestion by re-analysing the
published data using a Bayesian technique. This re-analy-
sis showed 13 % fewer myocardial infarctions among
patients treated with non-atenolol β-adrenergic blockers
than among patients treated with atenolol. We argue that
non-atenolol β-adrenergic blockers should continue to be
fundamental in the treatment of hypertension.
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Table 1: Risk ratios for myocardial infarction among hypertensive patients treated with non-atenolol versus atenolol β-blockers
Number of studies Mean Risk ratio Median risk ratio Credibility interval Probability of risk ratio ≤ 0.90
2.5 – 97.5 % 5 – 95 %
Studies that only included comparison with 
non-β-blockers
8 0.836 0.828 0.633 – 1.078 0.664 – 1.031 0.836
Studies that only included comparison with 
placebo
6 0.918 0.906 0.711 – 1.172 0.734 – 1.125 0.475
All studies included 14 0.868 0.867 0.727 – 1.023 0.750 – 0.992 0.689
All studies except MRC Old atenolol versus 
other antihypertensive drugs
13 0.882 0.883 0.742 – 1.039 0.758 – 1.016 0.616
Four outputs with 100 000 iterations each of Monte Carlo sampling with a Bayesian method giving ratios of risks of myocardial infarctions in 
hypertensive patients using non-atenolol β-adrenergic blockers versus using atenolol, respectively, with data from studies involving non β-blocker 
drugs, studies with placebo groups and with data from both kinds of studies